Skip to content

Biomatter

Computational technology platform for custom enzyme design and development.

Status unknownPublic sources — Collected from public sources, not yet cross-checked.Website

Biomatter is a biotech & life sciences company. It has raised $18 million in disclosed funding. Its latest round was a Series A of $18 million in November 2026.

Overview

No overview yet. It is written from sources once there are enough of them.

Funding

Total disclosed: $18M across 1 round. Computed only from sourced rounds.

  • Nov 12 · Series A

    Biomatter$18M

    Led by Astanor · with UVC Partners, +2

    Biotech & Life Sciences1 source

Investors

Questions and answers

What does Biomatter do?

Computational technology platform for custom enzyme design and development.

How much has Biomatter raised?

Biomatter has raised $18 million in disclosed funding across 1 round tracked by OSH.

Who has invested in Biomatter?

Investors in Biomatter include Astanor, UVC Partners, Inventure Partners, and Metaplanet.

Sources

  1. 1.Biomatter lands $18M to speed up enzyme development with AI — Tech.eu, Nov 12, 2026

Public sources — Collected from public sources, not yet cross-checked.Last verified Nov 12, 2026